Profile data is unavailable for this security.
About the company
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
- Revenue in EUR (TTM)3.93bn
- Net income in EUR443.50m
- Incorporated1998
- Employees5.36k
- LocationIpsen SA65 Quai Georges GorseBOULOGNE-BILLANCOURT 92100FranceFRA
- Phone+33 158335000
- Fax+33 158335001
- Websitehttps://www.ipsen.com/
More ▼
Mergers & acquisitions
| Acquired company | IPN:PAR since announced | Transaction value |
|---|---|---|
| ImCheck Therapeutics SAS | 45.98% | 405.93m |
Data delayed at least 15 minutes, as of Feb 27 2026 16:35 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | 424.98m | -613.62m | 10.91bn | 834.00 | -- | -- | -- | 25.67 | -3.78 | -3.78 | 2.62 | -10.71 | 0.5412 | -- | 6.97 | 602,009.60 | -79.01 | -76.52 | -105.26 | -96.54 | 95.82 | 96.16 | -145.98 | -340.73 | 2.68 | -2.17 | 4.29 | -- | 126.26 | 127.44 | -35.31 | -- | 4.99 | -- |
| Elanco Animal Health Inc | 3.99bn | -196.38m | 11.11bn | 9.40k | -- | 2.00 | 29.30 | 2.78 | -0.4848 | -0.4848 | 9.53 | 13.17 | 0.3631 | 1.28 | 5.62 | 501,595.80 | -1.79 | -2.26 | -2.01 | -2.53 | 54.99 | 55.59 | -4.92 | -7.41 | 1.08 | 1.15 | 0.3803 | -- | 6.22 | 7.59 | -168.64 | -- | -2.35 | -- |
| Neurocrine Biosciences Inc | 2.42bn | 405.11m | 11.23bn | 2.00k | 28.36 | 4.07 | 26.09 | 4.64 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| Zhangzhou Pientzhng Phrmctcl Co Ltd | 1.21bn | 298.64m | 12.16bn | 2.84k | 40.70 | 6.81 | -- | 10.07 | 4.01 | 4.01 | 16.21 | 23.99 | 0.5515 | 1.15 | 11.11 | 3,444,842.00 | 13.60 | 18.53 | 16.58 | 23.24 | 36.98 | 45.91 | 24.65 | 28.42 | 2.12 | -- | 0.0658 | 42.26 | 7.25 | 13.52 | 6.42 | 16.72 | 74.81 | 29.36 |
| Sino Biopharmaceutical Ltd | 3.78bn | 482.33m | 12.28bn | 23.06k | 24.49 | 2.84 | 12.21 | 3.25 | 0.247 | 0.2453 | 1.93 | 2.13 | 0.4317 | 2.83 | 3.98 | 1,433,824.00 | 9.56 | 12.16 | 18.52 | 20.91 | 81.77 | 80.75 | 22.15 | 26.50 | 1.28 | -- | 0.2071 | 27.19 | 10.18 | 3.56 | 3.93 | -7.01 | -7.91 | 6.66 |
| CSPC Pharmaceutical Group Ltd | 3.24bn | 502.56m | 12.34bn | 19.27k | 24.41 | -- | 53.28 | 3.81 | 0.4056 | 0.4056 | 2.61 | -- | -- | -- | -- | 1,400,839.00 | -- | 14.64 | -- | 19.49 | 66.23 | 72.50 | 15.54 | 19.11 | -- | -- | -- | 41.10 | -7.76 | 5.59 | -26.31 | 3.11 | 4.76 | 21.28 |
| Swedish Orphan Biovitrum AB (publ) | 2.65bn | 44.81m | 13.25bn | 1.89k | 304.90 | 3.62 | 35.69 | 5.00 | 1.30 | 1.30 | 81.42 | 109.12 | 0.3953 | 1.28 | 5.11 | 14,956,040.00 | 0.6663 | 3.92 | 0.8337 | 5.04 | 78.89 | 77.84 | 1.69 | 10.91 | 0.585 | 9.61 | 0.2336 | 0.00 | 8.50 | 13.10 | -87.70 | -31.82 | -3.93 | -- |
| Sichuan Biokin Pharmaceutical Co Ltd | 274.74m | -105.20m | 13.48bn | 2.52k | -- | 15.23 | -- | 49.08 | -2.14 | -2.14 | 5.54 | 17.37 | 0.2309 | 1.44 | 2.31 | 883,003.90 | -8.84 | 27.12 | -11.31 | 47.59 | 89.15 | 86.86 | -38.29 | 29.03 | 5.23 | -- | 0.3446 | 0.00 | 936.31 | 37.00 | 575.02 | 243.69 | 31.86 | -- |
| Torrent Pharmaceuticals Ltd | 1.18bn | 211.18m | 13.63bn | 16.11k | 64.56 | -- | 47.55 | 11.51 | 67.12 | 67.12 | 376.38 | -- | -- | -- | -- | 7,910,902.00 | -- | 9.54 | -- | 14.72 | 75.64 | 72.56 | 17.83 | 14.14 | -- | 16.34 | -- | 61.09 | 7.35 | 7.72 | 15.39 | 14.48 | 8.51 | 30.36 |
| Ipsen SA | 3.93bn | 443.50m | 13.84bn | 5.36k | 31.04 | 3.15 | 14.30 | 3.52 | 5.32 | 5.32 | 47.09 | 52.42 | 0.5875 | 2.85 | 5.30 | -- | 6.66 | 9.15 | 8.54 | 12.07 | 80.89 | 82.61 | 11.33 | 15.86 | 1.79 | 122.28 | 0.1845 | 20.03 | 9.92 | 7.90 | 24.61 | -4.01 | 18.50 | 6.96 |
| Viatris Inc | 11.96bn | -3.12bn | 14.55bn | 32.00k | -- | 1.14 | -- | 1.22 | -3.10 | -3.10 | 11.96 | 13.13 | 0.3417 | 2.09 | 4.90 | 441,387.50 | -8.93 | -0.1756 | -10.89 | -0.2096 | 39.36 | 40.66 | -26.13 | -0.5768 | 0.793 | 2.79 | 0.4868 | -- | -4.46 | 5.09 | -1,259.42 | -- | -3.10 | -- |
| Divi's Laboratories Ltd | 958.57m | 230.40m | 15.81bn | 18.30k | 68.58 | -- | 58.08 | 16.49 | 93.45 | 93.45 | 388.82 | -- | -- | -- | -- | 5,636,066.00 | -- | 15.81 | -- | 17.33 | 61.65 | 55.90 | 24.04 | 25.82 | -- | -- | -- | 35.19 | 19.31 | 11.65 | 36.94 | 9.74 | 3.98 | 13.40 |
| Innovent Biologics Inc | 1.41bn | 140.11m | 15.98bn | 6.19k | 110.26 | 8.53 | 79.74 | 11.30 | 0.7718 | 0.7718 | 7.85 | 9.97 | 0.5205 | 1.80 | 7.39 | 2,308,311.00 | 5.16 | -8.71 | 6.52 | -10.73 | 85.69 | 84.74 | 9.91 | -24.84 | 2.39 | -- | 0.1898 | -- | 51.82 | 55.17 | 90.79 | -- | 35.02 | -- |
Data as of Feb 27 2026. Currency figures normalised to Ipsen SA's reporting currency: Euro EUR
7.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 1.31m | 1.57% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 789.35k | 0.94% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 755.33k | 0.90% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 672.42k | 0.80% |
| Boston Partners Global Investors, Inc.as of 30 Jan 2026 | 664.70k | 0.79% |
| Geode Capital Management LLCas of 26 Feb 2026 | 583.51k | 0.70% |
| M&G Investment Management Ltd.as of 31 Oct 2025 | 541.17k | 0.65% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 480.22k | 0.57% |
| Oddo BHF Asset Management SASas of 30 Jan 2026 | 451.52k | 0.54% |
| Amundi Asset Management SASU (Investment Management)as of 25 Feb 2026 | 398.19k | 0.48% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
